Introduction
T acute lymphoblastic leukemia (T-ALL) is a very heterogeneous disease, characterized by several genetic alterations and polymorphic clinical features in children and adults. 1 Notably, about 60% of T-ALL shows increased Notch1 activity, 2 because of activating Notch1 mutations, typically found in two domains of the protein, the heterodimerization and the intra-cellular C-terminal proline (P), glutamic acid (E), serine (S) and threonine (T) rich (PEST) domain, or because of alterations in the Fbw7 gene, responsible for Notch1 intracellular domain (ICD) priming for degradation. 3, 4 Less frequently, alterations in p53 or PTEN genes are also found. 5 Constitutive activation of this signalling pathway confers to the cell a strong growth advantage, because of secondary effects on key regulators of cell proliferation, such as c-myc and p27 (Dohda et al. 6 ; Palomero et al. 7 ; Weng et al. 8 ). In addition, Notch activation can perturb the balance between apoptosis and survival toward the second through different mechanisms. Indeed, previous studies demonstrated that the NFkB signalling pathway is regulated and induced by Notch1 activation both by direct binding of Notch1 to RELB and NFKB2 promoters and indirectly, through the interaction of Notch1 with the kinase IKK, an important regulator of NFkB activity. 9 In addition to NFkB, regulation of cell survival by Notch1 ICD has partly been attributed to a reduction of the ubiquitination and degradation of the X linked inhibitor of apoptosis (XIAP), 10 or to an activation of PKB/AKT/mTOR pathway-mediated p53 inhibition. 11 In addition to Notch1, deregulated Notch3 signalling has been proposed to be important in T-ALL, in view of the oncogenic potential of the Notch3 ICD in transgenic mouse models. 12 As Notch3 mutations have not been reported in T-ALL 13 and are very rare in solid tumors, 14 it is possible that activation of this particular Notch receptor could beFat least in partFligand dependent. In this regard, activation of Notch3 by its ligand Dll4 expressed on angiogenic vessels has recently been shown to coordinate escape from quiescence leading to progressive tumor growth in a xenograft model of T-ALL. 15 Delivery of survival signals from endothelial to leukemia cells, in part mediated by the NFkB pathway, has been implicated in this phenomenon. 15 These data reinforced previous findings showing that Notch3 and the pre-T-cell receptor regulate NFkB activity in pre-malignant thymocytes and T lymphoma cells in mice. 16 Whether other survival pathways could be regulated by Notch3 signalling in T-ALL cells is currently unknown.
Mitogen-activated protein kinases (MAPKs) activation and in particular the balancing between phosphorylated extracellular signal-regulated kinase (P-ERK) and p38 (P-p38) has been shown to have a key role in the establishment of tumor dormancy in certain models. 17 In particular, studies by Aguirre-Ghiso et al. 18, 19 demonstrated that imbalances in the activity ratio of ERK to p38 signalling because of changes in the urokinase receptor pathway may determine the fate (that is, tumorigenicity versus dormancy) of different carcinoma cells. The level of phosphorylation and activity of these MAPKs is controlled by MAPK phosphatase 1 (MKP-1), a member of the threoninetyrosine dual-specificity phosphatase family that is regulated by stress conditions and is broadly expressed in cancer cells, where it appears to regulate p38 and/or JNK activity and their effects on cell proliferation and apoptosis. 20 In this study, intrigued by the detection of higher MKP-1 levels in aggressive compared with dormant T-ALL xenografts known to bear different levels of Notch3 activation, 15 we investigated the possibility that Notch3 might be involved in the control of MKP-1 levels. We found evidence that MKP-1 can be controlled by Notch3 by a mechanism involving control of protein stability. Furthermore, our results show that MKP-1 is broadly expressed in T-ALL cell lines and in primary T-ALL cells, and it modulates p38 and JNK activation and apoptosis under stress conditions or treatment with certain drugs. Finally, attenuation of MKP-1 expression delayed leukemia progression in mice. Altogether, these findings describe MKP-1 both as a novel mediator of the Notch3-induced anti-apoptotic activity and as new regulator of T-ALL growth.
Materials and methods

Cell lines and in vitro culture
The human T lymphoblastic cell lines MOLT-3, Jurkat, Loucy, CCRF-HSB-2 and CEM were purchased from ATCC (Manassas, VA, USA). TALL1 and DND41 cell lines were kindly provided by A Ferrando (Columbia University, New York, NY, USA). T-ALL cell lines were grown in RPMI 1640 medium supplemented with 10% fetal calf serum and 1% L-glutamine (Life Technologies, Grand Island, NY, USA) (complete RPMI). Primary T-ALL cells (PD-TALL) were obtained from BM of newly diagnosed ALL pediatric patients, according to the guidelines of the local ethics committees. PD-TALL cells were grown in MEM -medium (Invitrogen, Milan, Italy) supplemented with 10% fetal calf serum, 10% human heat inactivated AB þ serum, 1% penicillin/streptomycin, 1% Glutamax (all from Invitrogen), human IL7 (R&D Systems, Minneapolis, MN, USA), human SCF, human FLT3-ligand (both from Peprotech, London, UK) and insulin (Sigma-Aldrich, St Louis, MO, USA). GT and DT cell lines were derived from growing or dormant tumors obtained by injection of parental MOLT-3 cells subcutaneously (s.c.) into non-obese diabetic severe combined immunodeficent (NOD/SCID) mice in the presence or the absence of exogenous basic fibroblast growth factor (bFGF). 21 The murine dermal microvascular endothelial cell line SIEC was obtained from Dr A Vecchi (Mario Negri Institute, Milan, Italy). SIEC cells were cultured in Dulbecco's modified Eagle's medium supplemented with 20% fetal calf serum, 1 mM L-glutamine, 1% non essential amino acids, 1 mM Na pyruvate, EC growth supplement (Sigma-Aldrich) and heparin (100 mg/ml). Co-cultivation experiments and culture over recombinant murine Dll4 ligands have been performed as previously described. 15 In a set of experiments, T-ALL cell lines and primary T-ALL cells were treated with g-secretase inhibitors (GSIs) compound E (CalbiochemMerck, Darmstadt, Germany) and gSI (Sigma-Aldrich cat. no. S2188). For apoptosis induction, cells were treated with anisomycin, cisplatin, cytarabine, vincristine, methotrexate or, alternatively, were serum starved (for time and dose see experiment description).
Tumorigenicity assay
NOD/SCID mice were purchased from Charles River (Wilmington, MA, USA). Procedures involving animals and their care conformed to institutional guidelines that comply with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 12 December 1987). For tumor establishment, 7-9-week-old female mice were injected s.c. with 3.0 Â 10 6 MOLT-3 or DND41 cells in a 300 ml total volume into both dorsolateral flanks, and tumor growth was comparable in both flanks. In a set of experiments, cells were injected in combination with Matrigel (Becton-Dickinson, Franklin Lakes, NY, USA) and bFGF (Peprotech, 100 ng/ml) as previously described. 21 To test the effect of Dll4-Notch3 interaction blockade on MKP-1 expression in vivo, the anti-Dll4 monoclonal antibody (mAb) YM152F (courtesy of Dr M Yan, Genentech, San Francisco, CA, USA) was initially co-injected with tumor cells and subsequently administered intraperitoneally every 3 days (10 mg/g).
In all experiments, tumors were inspected twice weekly and measured by caliper; tumor volume was calculated with the following formula: tumor volume (mm
5, where L is the longest diameter, l is the shortest diameter and 0.5 is a constant to calculate the volume of an ellipsoid.
In another set of experiments, 1.0 Â 10 7 DND41 cells were injected intravenously into 7-9-week-old female mice.
Optical imaging of tumors
To perform in vivo imaging, tumor cells were transduced with a lentiviral vector encoding the Luciferase reporter gene 22 produced in 293T packaging cells as described before. 23 Bioluminescence images were acquired at several time points after cells injection using a highly sensitive, cooled CCD camera mounted on a ligh-tigh specimen box (IVIS Imaging System, Xenogen Corporation, Alemeda, CA, USA). Ten minutes before imaging, animals were anesthetized and injected intraperitoneally with 150 mg/kg of D-luciferin (Biosynth AG, Staad, Switzerland) in Dulbecco's phosphate-buffered saline. Signal intensity was quantified as average radiance within a region of interest prescribed around the tumor sites (photons/s/cm 2 ) using the LivingImage software (Xenogen).
Western blot analysis
Cell lysates were run on 7.5-10% polyacrylamide gels; separated proteins were then blotted for 2 h at 400 mA onto a nitrocellulose membrane. Immunoprobing was performed using: mouse mAb against P-p38, rabbit polyclonal Ab against p38, mouse mAb against P-p44/42, rabbit polyclonal Ab against p44/42, P-JNK1-2 and Notch1 ICD (all from Cell Signaling Technologies, Beverly, MA, USA), rabbit polyclonal Ab against human Notch3, rabbit polyclonal against MKP-1, JNK1-2, mouse mAb against ubiquitin (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-b-actin and mouse polyclonal anti-a-tubulin (both from Sigma-Aldrich), followed by hybridization with a 1:5000 diluted horseradish peroxidase-conjugated anti-rabbit or anti-mouse Ab (Amersham-Pharmacia, Little Chalfont, UK). For immunoprecipitation experiments, 500 mg of total cell lysate were immunoprecipitated with 4 mg of the indicated Ab conjugated with A/G plus agarose (Santa Cruz Biotechnology). In all experiments, equivalent amounts of cell extracts (50 mg per sample) were subjected to western blot analysis to determine MKP-1 and a-tubulin levels before immunoprecipitation. Specificity controls were run by replacing the anti-MKP-1 Ab with mouse IgG (not shown).
Antigens were identified by luminescent visualization using the SuperSignal kit (Pierce, Rockford, IL, USA). Signal intensity was measured using a Bio-Rad XRS chemiluminescence detection system (Biorad Laboratories, Milan, Italy). Numbers below the bands indicate the ratio between the indicated protein and a-tubulin or b-actin bands normalized by setting at 1 the value obtained from one selected sample.
Immunofluorescence analysis
Cells previously seeded over poly-lysine (Sigma-Aldrich) treated glass slides were formaldehyde-fixed, permeabilized and then incubated with rabbit anti-MKP-1 (Santa Cruz Biotechnology) primary Ab, washed and incubated with the goat anti-rabbit Alexa Fluor 488 secondary Ab (Invitrogen).
Confocal laser scanning microscopy was carried out with a Zeiss LSM 510 microscope (Zeiss, Jena, Germany) using Argon (488 nm) laser source. Ten fields per sample were analyzed. Images were collected at magnification Â 200.
Reverse transcription-PCR and quantitative PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Complementary DNA was synthesized from 0.5-1 mg of total RNA using Superscript II first-strand system for RT-PCR (Invitrogen). For quantitative PCR analysis the SYBR green dye (Invitrogen) and ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA) were used. Relative quantification was done using the DDCt method, normalizing to b2-microglobulin mRNA. Primers used for PCR analysis: MKP1-for:
Transduction of cells with lentiviral vectors
Lentiviral vectors encoding short hairpin RNA (shRNA) targeted to MKP-1, Notch3 or a non-target shRNA as a control, were purchased from Sigma-Aldrich. The lentiviral vectorencoding MKP-1 was derived by replacing enhanced green fluorescent protein with the human MKP-1 coding DNA in the SalI/XbaI sites of pRRLsin.PTTs.hCMV.EGFP.Wpre. 23 Vector stocks were generated by a transient three-plasmid vectorpackaging system, as previously described. 24 For transduction of T-ALL cell lines, 200 ml of concentrated vector-containing supernatant were layered over target cells that had been seeded into 12-well culture plates at 1 Â 10 6 cells per well. After 6-9 h at 37 1C, the supernatant was replaced with 2 ml complete medium. Evaluation of gene silencing was carried out 72 h after transduction. MKP-1-silenced cells were obtained by selection in puromycin-containing medium (1 mg/ml). T-ALL cell lines stably expressing the Notch3 ICD were obtained by electroporation of parental cells with a pcDNA3.1-Notch3 ICD plasmid, 25 followed by selection in G418-containing medium (500 mg/ml). The pcDNA3.1-enhanced green fluorescent protein plasmid was used as a control.
Cytofluorimetric analysis
PC5-labelled mAb against human CD5 (Coulter Beckman, Brea, CA, USA) was used for the detection of T-ALL cells in blood samples ex vivo. Apoptosis evaluation was performed using the Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Penzberg, Germany). P-p38 levels were analyzed by incubating 1 Â 10 6 permeabilized cells with rabbit anti-P-p38 primary mAb (Cell Signaling), followed by labelling with goat anti-rabbit Alexa Fluor 488 secondary Ab (Invitrogen). Samples were analyzed on an EPICS-XL cytofluorimeter using Expo32 software (Coulter, Fullerton, CA, USA).
AlphaScreen SureFire P-p38 MAPK assay P-p38 was quantified using AlphaScreen SureFire kit (Perkin Elmer, Waltham, MA, USA), as described by the manufacturer. Briefly, DND41 cells were initially transduced by lentiviral vectors encoding shNotch3 or the control shRNA and plated at a density of 1 Â 10 6 cells/ml in a 96-well plate. In some wells, anisomycin was added to raise P-p38 levels. One day later, cells were lysed and transferred (10 ml) to a 384-well plate (Perkin Elmer). In all, 12 ml of a reagent mix, containing the anti-P-p38 Ab were mixed with AlphaScreen streptavidin-donor beads and anti-IgG (Protein A)-acceptor beads, and added to each well. After 4-h incubation at room temperature, the plate was read on Envision, a multilabel Reader with HTS Alpha option (Perkin Elmer).
Statistical analysis
Results were expressed as mean value ± s.d. Statistical analysis of data was performed using Student's t-test or Mann-Whitney test. Differences were considered statistically significant when Pp0.05.
Results
Dormant tumors are characterized by increased p38 and ERK1/2 activation and lower MKP-1 levels compared with growing tumors
The balance between ERK and p38 has previously been reported to contribute to the establishment of dormancy of carcinoma cells. 18, 19 To investigate the level of activation of these MAPKs in T-ALL cells, we initially established dormant and aggressive tumors formed by MOLT-3 cells in the s.c. tissue of NOD/SCID mice. Our previous study indicated that human MOLT-3 cells lack tumorigenic potential and remain dormant in NOD/SCID mice, whereas a derivative of this cell line, termed MOLT-3-bFGF, bearing enforced expression of the angiogenic factor bFGF, forms aggressive tumors. 21 Western blot analysis showed higher phosphorylation of both p38 and ERKs in most dormant tumors compared with the aggressive ones (Figures 1a and b) . However, the P-ERK/P-p38 ratio was similar between the two groups of tumors (not shown), thus indicating that predominance of ERK over p38 signalling was not a prerogative of aggressive tumors in this model, as opposed to what was previously found by others for carcinoma cells 18, 19 Intriguingly, expression of MKP-1, a phosphatase involved in the control of MAPKs phosphorylation and activity, 26 was strongly increased in aggressive respect to dormant tumors at the protein level (Figures 1a and b) . The steady-state levels of MKP-1 transcripts were similar in the two sets of samples (Figure 1c) , thus suggesting that post-transcriptional mechanisms of regulation might be dominant for MKP-1 expression in this particular model. These findings suggest that MKP-1 could contribute to control MAPKs phosphorylation in T-ALL cells.
Finally, analysis of a panel of T-ALL cell lines disclosed that MKP-1 is broadly expressed in T-ALL cell lines albeit levels are heterogeneous (Figure 1d ). These results are important because they hint at a possible role of this phosphatase in the control of MAPKs activation in a subset of T-ALL cell lines.
Modulation of Notch3 activity changes MKP-1 protein expression
To investigate the possibility that MKP-1 could be downstream of Notch3, a Notch receptor differentially activated in dormant compared with growing tumors in this model, 15 we modulated Notch3 activity by different approaches. A common strategy to inhibit Notch signalling is by blocking receptor cleavage using GSI, a class of drugs that blocks receptor cleavage thereby leading to decreased levels of Notch ICD and signalling. 7 As Notch3 ICD-specific antibodies are not available, we initially validated the anti-Notch3 Ab used in this study for western blot analysis. To this end, lysates of 293T cells transiently transfected with plasmids encoding either Notch3 full-length or ICD proteins were used as reference to identify the band corresponding to Notch3 ICD (Supplementary Figure S1) . Notably, the antiNotch3 Ab did not cross-react with Notch1 ICD (Supplementary Figure S1) , which is also commonly detected in T-ALL cells. Treatment of four different T-ALL cell lines (MOLT-3, Jurkat, TALL1 and DND41) with CompE effectively reduced both Notch3 ICD and MKP-1 levels in T-ALL cell lines ( Figure 2a) ; similar results were obtained in MOLT-3 cells following treatment with a different GSI (Supplementary Figure S2) . This was done in order to confirm that the results we obtained were the consequence of the specific inhibition of Notch activation and were not the result of off-target effects related to the individual compound used.
We previously demonstrated that the Dll4 ligand is a powerful activator of Notch3 activation in MOLT-3 cells in vitro and in vivo. 15 Interestingly, MOLT-3 and Jurkat cells cultivated in vitro in the presence of recombinant murine Dll4 upregulated MKP-1 expression (Supplementary Figure S3) . Co-culture of MOLT-3 cells on murine EC expressing Dll4 raised MKP-1 levels, a phenomenon that was prevented by Dll4 neutralization (Supplementary Figure S3) . Moreover, Dll4 neutralization in vivo was strongly effective in reducing both Notch3 ICD 15 and MKP-1 in MOLT-3 tumors (Supplementary Figure S3) . Although these findings show that modulation of Notch activity perturbs MKP-1 levels, they do not allow to identify which Notch receptor is involved. To investigate this, we analyzed MKP-1 levels in MOLT-3 cells bearing forced up-modulation of (Figure 2b) . Moreover, analysis of MOLT-3 cells transduced by two different Notch3-specific shRNA showed a strong decrease in MKP-1 protein levels (Figure 2c, left panel) . Interestingly, this relationship seems to be dose dependent because higher was Notch3 silencing (shN3/2) and stronger was the reduction of MKP1 levels. Intrigued by these results, we sought to investigate whether modulation of Notch3 could affect MAPK activation in T-ALL cell lines. To this end, DND41 cells were used, as these cells contain measurable levels of P-p38 under standard in vitro culture conditions. Attenuation of Notch3 expression by shRNA decreased MKP-1 levels and strongly increased P-p38 levels in DND41 cells by immunoblotting analysis, without changing total p38 levels ( Figure 2c, mid panel) . Furthermore, similar results were obtained by quantification of P-p38 levels in DND41 cells by using the fluorescence-based Alphascreen Surefire kinase assay (Figure 2c, right panel) . Altogether, these results show that silencing of Notch3 induces p38 activation in T-ALL cell lines.
MKP-1 ubiquitination is affected by Notch signalling
Notably, quantitative RT-PCR analysis did not show significant variations of MKP-1 mRNA levels in T-ALL cell lines following GSI treatment (Supplementary Figure S4) or transduction with shRNA (not shown), not suggesting a transcriptional regulation of MKP-1 levels. Protein stability is another level at which MKP-1 expression is regulated and the mechanism involved is based on the ubiquitin-proteasome system. [27] [28] [29] [30] [31] Treatment with proteasome inhibitors was followed by an increase in MKP-1 levels, thus indicating that proteasome-mediated degradation contributes to regulate MKP-1 expression levels in these cells (Supplementary Figure S5) . We then evaluated MKP-1 ubiquitination after GSI treatment. Cell lysates were immunoprecipitated with anti-MKP-1 antibodies and then immunoblotted with an anti-ubiquitin Ab. Results showed increased MKP-1 ubiquitination in MOLT-3 and Jurkat cells treated with two different GSI (CompE and gSI) compared with controls ( Figure 3a) . Similar results were obtained when cell lysates were immunoprecipitated with anti-ubiquitin Ab, followed by immunoblotting with anti-MKP-1 Ab (Figure 3b ). In contrast, Notch3 ICD overexpression strongly decreased MKP-1 ubiquitination levels in these cells (Figure 3c ). Taken together, these results indicate that Notch3 levels contribute to regulate MKP-1 stability in T-ALL cell lines.
MKP-1 exerts an anti-apoptotic activity in T-ALL
These findings raised the issue of the biological role of MKP-1 in T-ALL cells. According to previous studies, despite a controversial role in cell proliferation, MKP-1 seems to exert 
Western blot analysis of MOLT-3 cells transfected by a Notch3 ICD expression plasmid (N3-ICD) versus control cells (enhanced green fluorescent protein (EGFP))
. Density values were normalized to the ratio measured in the control sample, which was set at 1. (c) Notch3 silencing reduces MKP-1 expression and activates p38 in T-ALL cell lines. Left panel, western blot analysis of MOLT-3 cells transduced by lentiviral vectors encoding two different Notch3-specific shRNA (shN3/1 and shN3/2) or the control shRNA. In all samples analyzed, density values were normalized to the ratio measured in the control sample, which was set at 1. Mid panel: following shN3/1 transduction of DND41 cells, Notch3, MKP-1, p38, P-p38 and a-tubulin levels were analyzed by immunoblotting, and quantification was performed by P-p38 AlphaScreen SureFire kit (right panel), as described in section 'Materials and methods'. Results are expressed as mean ± s.d. of two independent experiments; *Po0.05.
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substantial anti-apoptotic activity in tumor cells. 20 Initially, we observed that MKP-1 was expressed at higher levels in MOLT-3 primary cultures established from growing respect to dormant tumors (Figure 4a, left panel) . Accordingly, anisomycin, a proapoptotic antibiotic whose effect is inversely correlated to MKP-1 levels, 26 showed higher pro-apoptotic effects in cells derived from dormant tumors that express relatively low MKP-1 levels, compared with results obtained in cells from aggressive tumors (Figure 4a, right panel) . To further study MKP-1 biological activity in T-ALL cell lines, we transduced MOLT-3 cells by lentiviral vectors expressing MKP-1-coding sequence or a shRNA against MKP-1. Following evaluation of the efficiency of these manipulations (Figure 4b ), we challenged cells with different pro-apoptotic stimuli including anisomycin, 26 cisplatin 32 and serum starvation. As expected, MOLT-3 cells underwent marked phosphorylation of both p38 and JNK1-2 following anisomycin stimulation; moreover, P-p38 and P-JNK1-2 levels were in part dependent on the MKP-1 status in the cells (Figure 4c ). Annexin V staining showed that MKP-1 overexpression partially protected MOLT-3 cells against all these stimuli (Figure 4d, left panel) . Conversely, MKP-1 silencing significantly increased apoptotic response of MOLT-3 cells to these stimuli (Figure 4d, right  panel) . Similar results were obtained following MKP-1 silencing in DND41 cells (not shown). Importantly, we observed that MKP-1 attenuation increased apoptosis following incubation of MOLT-3 and DND41 cells with drugs used to treat T-ALL patients, including cytarabine, vincristine and methotrexate (Figure 4e ) Altogether, these findings indicate that MKP-1 is involved in the regulation of apoptosis of T-ALL cells.
MKP-1 attenuation modulates apoptosis and P-p38 levels in vivo
To obtain a preliminary estimate of the functions of MKP-1 in vivo, we obtained s.c. MOLT-3 and DND41 xenografts bearing normal or reduced MKP-1 levels. Three weeks after injection, implants of control T-ALL cells were bigger and apparently more vascularized, compared with those of MKP-1-deficient cells (Figure 5a) . Moreover, MKP-1-silenced xenografts contained significantly higher numbers of apoptotic cells (Figure 5b ) and higher P-p38 levels ( Figure 5c ) compared with controls (Po0.05). On the other hand, cell cycle profiles of xenografts formed by cells bearing reduced MKP-1 levels were similar to controls (not shown), indicating that MKP-1 did not markedly modulate T-ALL cell proliferation in vivo. Altogether, these results show that MKP-1 levels are important to regulate apoptosis in the xenograft microenvironment.
MKP-1 attenuation impairs tumorigenicity of T-ALL cell lines
To evaluate the possible importance of MKP-1 expression on tumorigenicity, MOLT-3 cells bearing normal or reduced MKP-1 levels were tagged with the luciferase gene and grown as xenografts in the s.c. tissue of NOD/SCID mice. MKP-1-deficient cells displayed a significant delay in tumor growth compared with controls, both by volume measurement and live imaging analyses (Figures 6a and b) . In contrast, MKP-1 overexpression did not as such confer tumorigenic properties to dormant MOLT-3 cells, in the absence of Notch3 activation (data not shown). Altogether, these results indicate that Notch3-triggered MKP-1 upregulation is one of the mechanisms that sustain tumor growth in this model, albeit not sufficient to induce escape from tumor dormancy alone.
Finally, to extend these findings to a more clinically relevant model of T-ALL, we silenced MKP-1 expression in DND41 cells, which were known to cause leukemia after intravenous injection. DND41 cells were subsequently labelled with the luciferase gene and injected intravenously in NOD/SCID mice. Using live animal bioluminescence imaging, we were able to demonstrate a reduced tumor load in mice receiving DND41 with attenuated MKP-1 levels compared with controls (Figure 6c) , which was associated with reduction in the percentages of circulating blasts Figure 6d) . Altogether, these results show a substantial contribution of MKP-1 to T-ALL growth in two different mouse models.
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Expression of MKP-1 in primary T-ALL cells and correlation with the other molecular variables
To investigate whether these findings, which were obtained by using T-ALL cell lines, could be clinically relevant, we analyzed MKP-1 expression in a small number (n ¼ 7) of pediatric T-ALL samples with well-characterized immunophenotype and Notch1/Fbw7 mutation analysis (Supplementary Table 1) . MKP-1 protein expression was rather heterogeneous in these samples (Figure 7a , left panel) and levels were comparable to those detected in MOLT-3 cells, thus indicating a similarity in this respect between T-ALL cell lines and primary samples. Moreover, an association was found between MKP-1 protein (Figures 7a and b) . The lack of complete overlap between MKP-1 and Notch3 levels is likely due to the outcome of various factors, which can modulate them in vivo. We also observed that low MKP-1 levels matched relatively high P-p38/p38 rations in primary T-ALL cells (Figure 7a ), in line with findings obtained in the xenograft model (Figure 1a) . Finally, to further investigate the influence of Notch on MKP-1 levels, 
Discussion
MKP-1 is a member of the dual-specificity phosphatases family, which is regulated at multiple levels including mRNA expression and stability, de novo transcription, protein stability and activity, and intracellular localization. 33 MKP-1 expression has been reported in various human epithelial tumors, 34 where it can modulate p38-and JNK-dependent apoptosis, for instance in response to certain drugs, 32 suggesting that at least in a subset of human cancers, MKP-1 expression may mediate chemoresistance.
In the T-cell lineage, it was recently reported that genetic ablation of MKP-1 impairs activation, proliferation and functions of normal murine T cells, associated with enhanced activation of JNK and reduced NFATc1 translocation into the nucleus, 35 but less was known about MKP-1 and hematopoietic malignancies.
Our study clearly showed that MKP-1 is broadly expressed in T-ALL cell lines and addressed its contribution to tumorigenesis in different xenograft models. We found that attenuation of MKP-1 expression significantly hamperedFalthough it did not completely blockFtumor formation by MOLT-3 and DND41 cells both when grown s.c. and as a real leukemia. Apoptosis was significantly increased in tumors lacking MKP-1, in agreement with in vitro findings showing that MKP-1-deficient cells survived less than controls following serum deprivation. As suboptimal feeding conditions are often encountered in the tumor microenvironment, because of the incapacity of angiogenesis to match the metabolic demand of tumors, it is tempting to speculate that MKP-1 could be required to limit the negative effects of SAPK activation on T-ALL cell viability, as previously observed with other cell types. 26 Although p38 has been involved in the regulation of apoptosis under stress conditions, 36 we cannot conclude that p38 is the key mediator of MKP-1 effects in T-ALL cells. Indeed, although P-p38 levels were in part determined by the MKP-1 status and treatment with the p38 inhibitor SB203580 invariably prevented serum starvation-induced p38 phosphorylation, apoptosis was reduced by SB203580 in certain T-ALL cell lines (such as DND41) but not in others (such as MOLT-3) (not shown). This finding suggests that different MAPKs or possibly novel MKP-1 targets could be involved in regulation of apoptosis by MKP-1 in a cell-dependent manner. 
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In this study, proliferation in tumors bearing different levels of MKP-1 and P-p38 was comparable. In other experimental models, however, increased P-p38 levels force tumor cells to exit the cell cycle and slow down proliferation. 17 This difference could reflect cell type-specific effects, as it is established that p38 MAPK is activated on cellular stress and often engages pathways that can block proliferation or promote apoptosis depending on the cell type considered. 37 A strength of this study is to provide a link between these observations regarding MKP-1 and Notch3, a Notch receptor endowed with oncogenic properties in transgenic mice, 38 that we found activated in aggressive T-ALL xenografts. 15 Notch3 is broadly expressed in T-ALL cellsFpossibly due to the fact that it is also a transcriptional target of Notch1 7 Fbut mediators of its biological activity, including pTa and NFkB, have only partially been characterized. 12, 38 Moreover, Notch3 has been shown to have a role in normal intrathymic T-cell development and pre-TCR selection of T cells. 39 Here, we show that Notch3 is intertwined with the negative regulation of MAPKs activity via MKP-1. The complex interplay between Notch and the Ras/MAPK signalling pathway has been previously appreciated in developmental systems; for example, negative cross-talk between LIN12 and Ras in Caenorhabditis elegans vulval development is mediated by LIP-1, a worm MAPK phosphatase regulated by Notch. 40 More recently, it has been shown that MKP-1 is a transcriptional target of Notch1 in muscle cells. 41 Our findings are consistent with these early observations and demonstrate the existence of a link between Notch3 and MKP-1 in T lymphoid cells. In future studies, it will be interesting to investigate whether additional MKP-1 family members can be regulated by Notch3.
A further element of novelty of this study regards the mechanism involved in the control of MKP-1 levels by Notch3. In general, altered Notch signalling translates into transcriptional activation of a set of target genes, in part uncovered through microarray studies. 7, 8 MKP-1, however, does not appear to be a canonical Notch3 transcriptional target, as MKP-1 mRNA levels did not undergo significant transcriptional changes in T-ALL cell lines following modulation of Notch3 levels. In our experiments, we observed a modest (two fold) increase in MKP-1 expression levels only following forced expression of Notch3 ICD in MOLT-3 cells (not shown). On the other hand, we disclosed a previously unrecognized effect of Notch3 on MKP-1 protein stability, consisting in a reduced MKP-1 ubiquitination in the presence of Notch3 activation. Conversely, MKP-1 ubiquitination increased when Notch signalling was blocked by GSI treatment. As it was previously unknown whether Notch signalling could regulate protein expression other than by activating a specific transcriptional program, this finding is important. Notch3 does not bind MKP-1 in immunoprecipitation studies (not shown), thus suggesting that its effects on MKP-1 protein stability could be mediated by other proteins, such as E3 ubiquitin ligases. Intriguingly, MKP-1 is known to be bound and targeted for degradation by S-phase Kinaseassociated Protein-2 (SKP-2), 30 an ubiquitin ligase regulated by Notch1: in the absence of Notch1, SKP-2 levels decrease leading to accumulation of some relevant SKP-2 targets, such as p27. 6, 42 In our experiments, indeed, SKP-2 levels were slightly reduced following GSI treatment of T-ALL cell lines (not shown). In any case, the amounts of SKP-2 co-immunoprecipitated with MKP-1 were comparable in all cases (not shown), indicating that the Notch3-mediated regulation of MKP-1 levels does not involve reduced binding of SKP-2 to its target. Thus, how activated Notch3 impairs MKP-1 ubiquitination remains ground for future studies. Moreover, further mechanisms of regulation of MKP-1 protein by Notch3, such as those mediated by microRNAs at the post-transcriptional level, cannot be excluded.
In conclusion, the possible connection between the Notch and the MAPK pathwaysFthat MKP-1 could mediateFcould have far-reaching implications for understanding the pathogenesis and treatment of T-ALL as well as for physiological processes involving Notch3.
